Medical Oncology Hematology Consultants PA

Medical Oncology Hematology Consultants PA was paid $7.67M by Medicaid between Jan 2018 and Dec 2024, across 33 billing codes. Its largest line is J9271, Injection, pembrolizumab, 1 mg — 72% of everything it billed.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	5,376	$131K
2019	4,622	$125K
2020	8,253	$535K
2021	6,243	$1.26M
2022	8,520	$2.88M
2023	10,434	$2.16M
2024incomplete	7,397	$584K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
J9271	Injection, pembrolizumab, 1 mg	72%	692	505	$5.54M
96413	Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance	7.0%	8,039	3,895	$540K
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	5.0%	7,549	5,717	$384K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	3.2%	886	494	$248K
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	3.0%	6,475	5,134	$231K
J0897	Injection, denosumab, 1 mg	1.5%	96	74	$113K
99215	Doctor's office visit, returning patient (complex)Prolong outpt/office vis	1.5%	1,698	1,262	$112K
J1437	Injection, ferric derisomaltose, 10 mg	1.3%	105	73	$97K
96375	Therapeutic injection; each additional sequential IV push	1.2%	5,892	2,586	$91K
96417		1.0%	2,020	1,062	$77K
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	<1%	1,636	990	$49K
96367		<1%	2,576	1,343	$42K

21 more codes

J1453	Injection, fosaprepitant, 1 mg	<1%	436	$34K
J2469	Injection, palonosetron hcl, 25 mcg	<1%	1,393	$23K
96415		<1%	1,147	$19K
99204	Doctor's office visit, new patient (more involved)	<1%	232	$17K
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	1,526	$14K
99205	Prolong outpt/office vis	<1%	72	$9K
99232	Hospital visit by a doctor, follow-up day	<1%	218	$7K
99233	Hospital visit by a doctor, follow-up day (complex)	<1%	131	$5K
99223	Prolong inpt eval add15 m	<1%	47	$5K
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	5,381	$4K
96411		<1%	89	$3K
96401		<1%	76	$3K
99203	Doctor's office visit, new patient (routine)	<1%	31	$2K
99222	Initial hospital care, per day, moderate complexity	<1%	22	$2K
J9045	Injection, carboplatin, 50 mg	<1%	117	$1K
J1200	Injection, diphenhydramine hcl, up to 50 mg	<1%	1,798	$748.37
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour	<1%	54	$598.31
96361	Intravenous infusion, hydration; each additional hour	<1%	52	$593.03
J7030	Infusion, normal saline solution , 1000 cc	<1%	216	$410.49
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established)	<1%	43	$155.03
36591		<1%	100	$147.60

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialHIMELSTEIN, AMDREW (PRESIDENT)